Phase 4 N=34 Octylseal Surgical Adhesive in General Surgery
Wounds
Primary: Wound Length Closure — 28.97; 21.00 milimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Pharmacological Treatment of Rett Syndrome With Statins
Rett Syndrome
Primary: Gait Velocity as Measured by GAITRite System — 58.6 cm/sec
Phase 3 N=66 "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"
Acne Vulgaris
Primary: Lesion Counts (Total, Inflammatory and Non-inflammatory) — 18.4; 13.4; 15.8; 9.9 Lesions
Phase 2 N=12 Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
Alopecia Areata
Primary: Total Number of Responders — 8 Participants
Phase 2 N=365 Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…
Phase 2 N=80 Nicotinic Receptors and Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Neurocognitive Efficacy — 0.6; 2.1 MATRICS Neurocognitive T score — p=0.89
N/A N=3,827 Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
Neuralgia
Primary: Percentage of Participants With Adverse Drug Reaction — 15.03 Percentage of Participants
Phase 3 N=375 The Efficacy and Safety of PRC-063 in Adult ADHD Patients
ADHD
Primary: Change From Baseline in Clinician-administered ADHD-5-Rating Scale Total Score — 24.2; 19.9; 24.0; 18.7 units on a scale — p=0.6750
Phase 2 N=60 Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change
N/A N=263 MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study
Femoral Arteriotomy Closure
Primary: Time to Hemostasis — 65.4 seconds
Phase 2 N=20 Atrasentan Spermatogenesis and Testicular Function
Nephropathy · Diabetes
Primary: Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26 — 23.5 percentage of participants
N/A N=40 Study to Predict the Benefits of First-line Humidification Use and Comparison of the Effect of ThermoSmart™ and no Humidification on Adherence
Obstructive Sleep Apnea
Primary: Adherence — 4.7; 5.0 hours per night
N/A N=1,020 Registry on WATCHMAN Outcomes in Real-Life Utilization
Patients With Atrial Fibrillation at Risk for Thrombus Formation, Thromboembolism, Stroke
Primary: Procedural Complications — 2.8 percentage of participants
Phase 2 N=16 Clomiphene Citrate for Treatment of Acromegaly
Acromegaly
Primary: IGF-1 Levels — 424 ng/mL — p=< 0.05
Phase 2 N=53 A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
Mood Disorder · Mental Disorder Diagnosed in Childhood · Attention Deficit and Disruptive Behavior Disorder
Primary: Percentage of Participants That "Much Improved" (Score of 2) in, or "Completely Recovered" (Score of 1) From Their Irritability Severity, as Measured With the Clinical…